Related Experiment Video
Updated: Jan 17, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
New drugs for the management of tuberculosis
Gail B Cross1,2,3,4
1Burnet Institute.
Purpose Of Review:
This review summarizes recent and emerging advances in tuberculosis (TB) treatment, focusing on new therapeutics, repurposed agents, and shortened treatment regimens. It aims to contextualize key developments within the evolving TB treatment landscape and assess their potential to transform clinical management of both drug-susceptible and drug-resistant disease.
Recent Findings:
Evidence from landmark trials, including Nix-TB, ZeNix, TB-PRACTECAL, STREAM, Study 31/A5349, SHINE, TRUNCATE-TB, endTB and BEAT-TB has supported the use of licensed, repurposed, and novel agents as new treatment strategies. These studies have demonstrated the feasibility of treatment-shortening regimens for drug-susceptible TB and improved outcomes for multidrug-resistant TB. Progress has expanded the therapeutic armamentarium, with promising regimens incorporating new agents, higher-dose rifamycins, and safer, all-oral combinations.
Summary:
These advances have direct implications for clinical practice, offering shorter, safer, and more effective treatment options. Adoption of these new regimens into treatment guidelines will allow us to reduce treatment burden, improve adherence, and lower the risk of adverse effects. Continued optimization of drug combinations, dosing strategies, and safety profiles will be essential to achieving durable, scalable treatment options. Future research should prioritize regimen simplification, host-directed therapies, and tools for predicting and monitoring treatment response to support personalized, globally accessible TB care.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Combined Effects of Drugs: Synergism
Such synergistic combinations...

